KSQ Therapeutics Stock

ksqtx.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $257.46MM

KSQ Therapeutics is the developer of a genome-scale precision functional genomics platform, called CRISPRomics, designed to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed.

Register for Details

For more details on financing and valuation for KSQ Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for KSQ Therapeutics.

Register Today

Team

Management Team

David Meeker MD
Chief Executive Officer & Board Member
David Sabatini Ph.D
Co-Founder
Jonathan Weissman Ph.D
Co-Founder
John Trzupek Ph.D
Interim Chief Financial Officer & Head, Corporate Development
William Hahn MD
Co-Founder
Frank Stegmeier Ph.D
Chief Scientific Officer
Tim Wang Ph.D
Co-Founder

Board Members

David Meeker MD
George Golumbeski Ph.D
David Berry Ph.D
Flagship Pioneering
Pearl Huang Ph.D
Theo Melas-Kyriazi
Alan Crane
Polaris Partners
James Gilbert
Flagship Pioneering
Richard Moscicki MD

Other companies like KSQ Therapeutics in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

KSQ Therapeutics Enhances Board of Directors with Two Appointments
KSQ Therapeutics, a biotechnology company using CRISPR technology to enable the company’s powerful discovery engine to achieve higher probabilities of
Updated on: Oct 1, 2023